Related Experiment Videos
Retention of transforming growth factor beta1 using functionalized dextran-based hydrogels
Marion Maire1, Delphine Logeart-Avramoglou, Marie-Christelle Degat
1Laboratoire de Bio-ingénierie de Polymères Cardiovasculaires, ERIT-M Inserm 0204, X. Bichat Hospital, Paris, Université Paris 13 and Université Paris 7, 75877 Paris Cedex 18, France.
Biomaterials
|December 4, 2004
Summary
Functionalized dextran hydrogels effectively bind and release transforming growth factor-beta1 (TGF-beta1). These novel entrapment systems show promise for stabilizing proteins like TGF-beta1 for therapeutic applications.
Area of Science:
- Biomaterials Science
- Polymer Chemistry
- Drug Delivery Systems
Background:
- Functionalized dextrans (FD) are anionic polymers with binding capacity for transforming growth factor-beta1 (TGF-beta1).
- Hydrogels offer potential as matrices for protein delivery and stabilization.
Purpose of the Study:
- To investigate the capacity of dextran-based hydrogels containing FD to bind and release recombinant human TGF-beta1 (rhTGF-beta1).
- To characterize the influence of FD content and crosslinker feeding ratio (CFR) on hydrogel properties and protein release kinetics.
Main Methods:
- Hydrogels were prepared by crosslinking native dextran and FD using sodium trimetaphosphate.
- Hydrogel particles (1-1.6mm diameter) were characterized with varying FD amounts and CFR.
- In vitro release studies were conducted to assess rhTGF-beta1 binding and release kinetics.
Main Results:
- rhTGF-beta1 release kinetics were dependent on FD content and CFR.
- Increased negative charges in the hydrogel matrix, from phosphate linkages and FD, enhanced rhTGF-beta1 retention.
- Highly crosslinked hydrogels with 18% FD retained up to 88% of rhTGF-beta1, with confirmed bioactivity of released protein.
Conclusions:
- Functionalized dextran hydrogels demonstrate significant capacity for binding and controlled release of rhTGF-beta1.
- These hydrogels serve as effective entrapment systems, offering stabilization and protection for rhTGF-beta1.
- The developed hydrogels hold potential for applications involving other therapeutic proteins.